Company Overview
About Alumis
Alumis is a South San Francisco-based clinical-stage biopharmaceutical company founded in 2021 by Martin Babler and Joseph Arol, with a focus on developing precision oral therapies for patients with serious immune-mediated diseases. The company's lead program, ESK-001, is a highly selective TYK2 (tyrosine kinase 2) inhibitor targeting conditions including moderate-to-severe plaque psoriasis, systemic lupus erythematosus (SLE), and inflammatory bowel disease. TYK2 inhibition is a validated immunology mechanism — Bristol Myers Squibb's Sotyktu (deucravacitinib) was the first approved TYK2 inhibitor — and Alumis is developing what it believes is a next-generation molecule with improved selectivity.
Business Model & Competitive Advantage
Alumis completed an initial public offering on the Nasdaq stock exchange in June 2024 under the ticker symbol ALMS, raising capital to fund Phase 2 and Phase 3 clinical trials. Prior to the IPO, the company raised over $400M in private funding from investors including a16z Bio + Health, Foresite Capital, RA Capital Management, and others. The company's precision analytics platform combines genomic, biomarker, and clinical data to identify patient subpopulations most likely to respond to TYK2 inhibition — enabling smarter trial design and potential companion diagnostic development.
Competitive Landscape 2025–2026
Alumis competes in the high-value immunology market alongside established biologics (Humira, Skyrizi, Dupixent) and the growing class of oral small molecules (Sotyktu, JAK inhibitors). Its differentiation thesis is that ESK-001 can deliver biologic-comparable efficacy in an oral pill format with a potentially better safety profile than JAK inhibitors, which carry FDA black box warnings. Success in psoriasis could pave the way for label expansions into lupus and IBD — both large, underserved markets.
Key Differentiators
Emerging Innovator
Alumis is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Similar Brands
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
Compare Alumis with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Alumis? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Alumis Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Alumis vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →